Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Public ClinicalTrials.gov record NCT07478172. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults withNeuromuscular Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This single-arm pilot study evaluates the effects of whole-body electrical muscle stimulation (WB-EMS) exercise on neuromuscular and physical function in adults with neuromuscular disease (NMD). Due to motor unit impairments, NMD patients often cannot tolerate traditional exercise. WB-EMS bypasses voluntary activation limits by directly stimulating muscle contractions. Up to 50 adults with conditions like ALS, SMA, and MG will undergo 20-minute supervised WB-EMS sessions (1-2 times weekly for 4-8 weeks) using the Katalyst system. Outcomes include neural excitability (TMS), motor unit behavior (EMG, NCS), functional tests (walk, balance, strength), and patient-reported fatigue, pain, and quality of life. Strict safety monitoring and exclusion criteria are in place. This study will provide preliminary data on WB-EMS as a potential exercise modality for NMD.
Study identification
- NCT ID
- NCT07478172
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 50 participants
Conditions and interventions
Conditions
- Neuromuscular Diseases (NMD)
- Amyotrophic Lateral Sclerosis
- Myasthenia Gravis
- Lambert-eaton Myasthenic Syndrome
- Primary Lateral Sclerosis
- Spinal Muscular Atrophy
- Charcot Marie Tooth Disease (CMT)
- Fascioscapulohumeral Muscular Dystrophy
- Inclusion Body Myositis
- Mitochondrial Myopathy
- Nemaline Myopathy
- Centronuclear Myopathy
- Postpolio Syndrome
- Pompe Disease (Late-onset)
- Chronic Inflammatory Demyelinating Polyneuropathy
- Hereditary Spastic Paraplegia
- Postural Orthostatic Tachycardia Syndrome (POTS)
- Progressive Muscular Atrophy
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 9, 2026
- Primary completion
- Dec 30, 2030
- Completion
- Jan 6, 2031
- Last update posted
- Mar 16, 2026
2026 – 2031
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| NextGen Precision Health Building, Clinical and Translational Science Unit | Columbia | Missouri | 65211 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07478172, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 16, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07478172 live on ClinicalTrials.gov.